Intrapatient dose escalation to 800 mg/m(2) pemetrexed is safe and feasible in patients with advanced non-small cell lung cancer (NSCLC) who have had prior chemotherapy.

中國醫藥大學機構典藏 China Medical University Repository, Taiwan > 台中附設醫院 > 會議論文 > Item 310903500/27154

請使用永久網址來引用或連結此文件: http://ir.cmu.edu.tw/ir/handle/310903500/27154

題名:	Intrapatient dose escalation to 800 mg/m(2) pemetrexed is safe and feasible in patients with advanced non-small cell lung cancer (NSCLC) who have had prior chemotherapy.
作者:	Lee, JS;Hsia, TC;Yang, CH;Heo, DS;Chang, GC;Park, K;Kim, SW;Yildirim, H;Reece, WHH;Lehnert, M
貢獻者:	附設醫院 Natl Canc Ctr, Goyang, South Korea;China Med Univ Hosp, Taichung, Taiwan;Natl Taiwan Univ Hosp, Taipei, Taiwan;Seoul Natl Univ Hosp, Seoul 110744, South Korea;Taichung Vet Gen Hosp, Taichung, Taiwan;Sungkyunkwan Univ, Sch Med, Seoul, South Korea;Asan Med Ctr, Seoul, South Korea;Osmangazi Univ, Eskisehir, Turkey;Eli Lilly Australia, Sydney, NSW, Australia;Eli Lilly Asian Operat, Hong Kong, Hong Kong, Peoples R China
日期:	2005
上傳時間:	2010-09-20 13:54:53 (UTC+8)
出版者:	AMER SOC CLINICAL ONCOLOGY
關聯:	JOURNAL OF CLINICAL ONCOLOGY 23(16):647S-647S
顯示於類別:	[台中附設醫院] 會議論文

文件中的檔案:

沒有與此文件相關的檔案.

在CMUR中所有的資料項目都受到原著作權保護.

TAIR相關文章